Abstract 5083
Background
DHP107 is a novel oral formulation composed of lipid based components and paclitaxel. DHP107 showed efficacy and safety comparable to IV paclitaxel in patients (pts) with AGC {Ann Oncol 2018}. DHP 107 was approved for marketing in 2016 for gastric cancer in Korea as first oral paclitaxel in the world. Another phase II clinical trial of DHP107 for PKs in breast cancer is ongoing in USA.
Methods
This trial is conducted using Simon’s optimal two stage design, and planned to proceed to stage 2, if ≥ 2 of 9 pts showed objective response in stage 1. DHP107 is considered adequately effective to proceed into phase III trial if ≥ 9 of 34 showed PR in stage 2. Subjects are eligible for the study regardless lines of endocrine therapy. Pts are administrated with DHP107 (200mg/m2 po bid D1, 8 & 15 q4wks) and response evaluation (RECIST v1.1) was done every 8wks (±1w). The primary tumor assessment was done by investigator’s review (IR). Independent central review (ICR) was followed for sensitivity analysis. Primary endpoint is objective response rate (ORR) and secondary endpoints are progression free survival (PFS), overall survival (OS), disease control rate (DCR) and safety.
Results
Total 36 subjects (including 11 TNBC pts) were enrolled during Dec 2017 until Oct 2018. Per Protocol set (PPS) was composed of 33 pts and 14 pts are still on treatment. Safety Analysis set (SAS) included 36 pts. ORR was 48.5% (CR 0%; PR 48.5%) by the IR vs 36.4% (CR 0%; PR 36.4%) by ICR. DCR was similar between the investigator’s decision (90.9%) and ICR (84.9%). Most common adverse events (AEs) were neutropenia; Gr. 3/4 Neutropenia (75%), Anemia (16.7%) and Peripheral neuropathy (5.6%). There were 2 SAEs related to Gr. 3/4 neutropenia without fever. One patient discontinued due to Gr 3 peripheral neurotoxicity. There was no treatment-related toxic death.
Conclusions
Based on confirmed PR (n = 16/33, 48.5%), DHP107 demonstrated adequate efficacy with manageable toxicity in the first line HER2 negative recurrent/metastatic breast cancer patients. Phase III trial in breast cancer is ongoing in Korea and China.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Daehwa Pharmaceuticals. Co. Ltd.
Funding
Daehwa Pharmaceuticals. Co. Ltd.
Disclosure
K.S. Lee: Advisory / Consultancy: Roche; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Norvatis; Advisory / Consultancy: Lilly; Research grant / Funding (institution): Dong-A pharm. K. Lee: Advisory / Consultancy, Speaker Bureau / Expert testimony, Consulting role & Lecture fee: AstraZeneca; Advisory / Consultancy, Lecture fee: Bayer; Advisory / Consultancy, Lecture fee: Eisai; Advisory / Consultancy, Lecture fee: Ono Pharmaceuticals; Advisory / Consultancy, Speaker Bureau / Expert testimony, Consulting role & Lecture fee: Roche; Speaker Bureau / Expert testimony, Lecture fee: Eli Lilly; Advisory / Consultancy, Lecture fee: Samsung Bioepis. J. Sohn: Research grant / Funding (institution): MSD; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Norvatis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): GSK; Research grant / Funding (institution): CONTESSA; Research grant / Funding (institution): Diichi Sankyo. S. Kim: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Sanofi-Genzyme; Research grant / Funding (institution): Dongkook. All other authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract